New injection could shrink nasal polyps without surgery
NCT ID NCT07484230
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This Phase 3 trial tests itepekimab, an injected antibody, in 20 Japanese adults with chronic sinusitis and nasal polyps that are not well-controlled despite surgery or steroids. The study measures changes in polyp size and nasal congestion over 52 weeks. It aims to see if the drug is safe and effective as a standalone treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- itepekimab (a monoclonal antibody injection)
- What this could lead to
- If it works, it could offer a new treatment option for people with nasal polyps that are not controlled by current therapies.
- What could go wrong
- This is a small, early-stage Phase 3 trial with only 20 participants, so results may not apply to everyone. The drug may not work better than placebo or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink nasal polyps and restore smell?
- Triple-Action nasal spray could ease chronic sinusitis
- 3D-Printed nose models could boost sinus rinse results
- Sinus surgery may ease sleep problems in nasal polyp patients
- Real-World check: do new biologics really help severe nasal polyps?
- New study digs into how mepolizumab changes nose bacteria and genes in asthma patients